Legal & General Group’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-19,787
| Closed | -$399K | – | 3471 |
|
|
2026
Q1 | $399K | Sell |
19,787
-4,031
| -17% | -$65K | ﹤0.01% | 2414 |
|
|
2025
Q4 | $385K | Sell |
23,818
-136
| -0.6% | -$1.8K | ﹤0.01% | 2485 |
|
|
2025
Q3 | $292K | Buy |
23,954
+19,752
| +470% | +$273K | ﹤0.01% | 2555 |
|
|
2025
Q2 | $47.5K | Sell |
4,202
-4,338
| -51% | -$53K | ﹤0.01% | 2717 |
|
|
2025
Q1 | $98.6K | Buy |
8,540
+396
| +5% | +$4.04K | ﹤0.01% | 2668 |
|
|
2024
Q4 | $69K | Buy |
8,144
+1,494
| +22% | +$15.5K | ﹤0.01% | 2747 |
|
|
2024
Q3 | $77.1K | Buy |
6,650
+270
| +4% | +$3.4K | ﹤0.01% | 2746 |
|
|
2024
Q2 | $75.2K | Buy |
6,380
+3,784
| +146% | +$44.2K | ﹤0.01% | 2757 |
|
|
2024
Q1 | $30.8K | Hold |
2,596
| – | – | ﹤0.01% | 2848 |
|
|
2023
Q4 | $31.8K | Buy |
2,596
+644
| +33% | +$5.86K | ﹤0.01% | 2883 |
|
|
2023
Q3 | $18.8K | Sell |
1,952
-405
| -17% | -$4.14K | ﹤0.01% | 3060 |
|
|
2023
Q2 | $21.2K | Hold |
2,357
| – | – | ﹤0.01% | 3093 |
|
|
2023
Q1 | $18.5K | Hold |
2,357
| – | – | ﹤0.01% | 3085 |
|
|
2022
Q4 | $15.9K | Hold |
2,357
| – | – | ﹤0.01% | 3197 |
|
|
2022
Q3 | $34K | Buy |
2,357
+304
| +15% | +$4.25K | ﹤0.01% | 3065 |
|
|
2022
Q2 | $20K | Sell |
2,053
-720
| -26% | -$7.94K | ﹤0.01% | 3237 |
|
|
2022
Q1 | $40K | Hold |
2,773
| – | – | ﹤0.01% | 3042 |
|
|
2021
Q4 | $37K | Buy |
2,773
+321
| +13% | +$5.11K | ﹤0.01% | 3098 |
|
|
2021
Q3 | $42K | Hold |
2,452
| – | – | ﹤0.01% | 3025 |
|
|
2021
Q2 | $59K | Buy |
2,452
+786
| +47% | +$20.6K | ﹤0.01% | 2899 |
|
|
2021
Q1 | $43K | Buy |
1,666
+348
| +26% | +$9.14K | ﹤0.01% | 2858 |
|
|
2020
Q4 | $25K | Hold |
1,318
| – | – | ﹤0.01% | 3002 |
|
|
2020
Q3 | $17K | Sell |
1,318
-418
| -24% | -$5.23K | ﹤0.01% | 3026 |
|
|
2020
Q2 | $21K | Sell |
1,736
-363
| -17% | -$3.86K | ﹤0.01% | 3051 |
|
|
2020
Q1 | $16K | Sell |
2,099
-323
| -13% | -$4.36K | ﹤0.01% | 2993 |
|
|
2019
Q4 | $40K | Buy |
2,422
+478
| +25% | +$6.24K | ﹤0.01% | 2905 |
|
|
2019
Q3 | $23K | Hold |
1,944
| – | – | ﹤0.01% | 3086 |
|
|
2019
Q2 | $43K | Buy |
+1,944
| New | +$45.6K | ﹤0.01% | 2832 |
|
Other funds holding KALV
Legal & General Group's KALV Position: Q2 2026 in Review
Legal & General Group sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 19,787 shares — an estimated $399K sold.
Legal & General Group first reported a position in KALV in Q2 2019 and held it in 28 quarters. The position peaked at $399K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Legal & General Group reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Legal & General Group sold 19,787 KalVista Pharmaceuticals shares in Q2 2026, an estimated $399K.
- Legal & General Group first reported a position in KalVista Pharmaceuticals in Q2 2019 and held it in 28 quarters.
- Legal & General Group's KalVista Pharmaceuticals position peaked at $399K in Q1 2026.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.